Latest News-Innovent Biologics,Inc Mediaroom_Page

FDA Advisory Committee Votes to Recommend Additional Data for Sintilimab Submission

SAN FRANCISCO, and SUZHOU, China, Feb. 11, 2022 /PRNewswire/ -- The U.S. Food and Drug Administrati...

2022-02-11 10:44 3516

Innovent Announces the Approval of Pemazyre® (pemigatinib) in Hong Kong Market for the Treatment of Adults With Locally Advanced Or Metastatic Cholangiocarcinoma With A FGFR2 Fusion Or Rearrangement That Have Progressed After At Least One Prior Line Of Systemic Therapy

SAN FRANCISCO and SUZHOU, China, Jan. 24, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ...

2022-01-24 15:22 4059

Innovent and Eli Lilly and Company Announced Final Clinical Results and Biomarker Analysis of Phase Ib Study of TYVYT® (Sintilimab Injection) Plus Bevacizumab Biosimilar Injection for Advanced Hepatocellular Carcinoma at ASCO GI Annual Meeting 2022

SAN FRANCISCO and SUZHOU, China, Jan. 22, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2022-01-22 08:00 8162

Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics Announce Non-Exclusive License Agreement for Clinically Validated BCMA CAR Construct

SEATTLE, SAN FRANCISCO, SAN JOSE, Calif., NANJING, China, SUZHOU, China and SHANGHAI, Jan. 11, 2022...

2022-01-11 05:30 3514

Innovent Announces NMPA of China Acceptance of a Supplemental New Drug Application for TYVYT® (Sintilimab Injection plus Bevacizumab Biosimilar Injection and Chemotherapy in Patients with EGFR-mutated Non-squamous Non-small Cell Lung Cancer who Progressed after EGFR-TKI Therapy

SAN FRANCISCO and SUZHOU, China, Dec. 24, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ...

2021-12-24 16:51 10063

Innovent Announces Pivotal Phase 2 Results for Parsaclisib (PI3Kδ inhibitor) Presented at ASH 2021 Show Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma

SAN FRANCISCO and SUZHOU, China, Dec. 14, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2021-12-14 08:00 2847

Innovent and IASO Announced Updated Clinical Data of BCMA CAR-T Therapy in Oral Presentation at 2021 ASH Annual Meeting

SAN FRANCISCO, U.S. and SUZHOU, China, Dec. 13, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Inn...

2021-12-13 08:00 2950

Innovent Releases Results of a Phase 1 Clinical Study of IBI362, a Dual Glucagon-like Peptide-1 and Glucagon Receptor Agonist in Chinese Patients with Type 2 Diabetes at the International Diabetes Federation Congress 2021

SAN FRANCISCO and SUZHOU, China, Dec. 7, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent")...

2021-12-07 08:00 3217

Innovent and Lilly Announce Successful Expansion of Sintilimab in China National Reimbursement Drug List to Include Three Additional First-Line Indications

SAN FRANCISCO, INDIANAPOLIS, and SUZHOU, China, Dec. 3, 2021 /PRNewswire/ -- Innovent Biologics, In...

2021-12-03 12:37 3806

Innovent Biologics and Ascentage Pharma Announce the China NMPA Approval for China's First Third-Generation BCR-ABL Inhibitor Olverembatinib for the Treatment of Chronic Myeloid Leukemia

SUZHOU, China, SAN FRANCISCO and ROCKVILLE, Md., Dec. 1, 2021 /PRNewswire/ -- Innovent Biologics, I...

2021-12-01 08:00 2690

Innovent Releases the ORIENT-31 Phase 3 Study First Interim Analysis Results of Sintilimab plus BYVASDA (bevacizumab biosimilar injection) and Chemotherapy in Patients with EGFR-mutated Nonsquamous Non-small Cell Lung Cancer who Progressed After EGFR-TKI Therapy at ESMO Virtual Plenary 2021

SAN FRANCISCO and SUZHOU, China, Nov. 22, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2021-11-22 08:16 2947

Innovent Announces Inclusion of the Company's Stock (01801.HK) in the Hang Seng China Enterprises Index

SAN FRANCISCO and SUZHOU, China, Nov. 22, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2021-11-22 08:00 3458

Innovent Announces the Results of the Phase Ib Clinical Trial of IBI302, a First-in-class Anti-VEGF and Anti-Complement Bi-specific Fusion Protein for Neovascular Age-Related Macular Degeneration at 2021 American Academy of Ophthalmology

SAN FRANCISCO and SUZHOU, China, Nov. 15, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2021-11-15 08:00 2573

Innovent Publishes the Preclinical Results of IBI319 (Anti PD-1/CD137 Bispecific Antibody) in Nature Communications

SAN FRANCISCO and SUZHOU, China, Nov. 8, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2021-11-08 08:00 2954

Innovent Announces NMPA Acceptance of a Supplemental New Drug Application for Sintilimab in Combination with Chemotherapy as First-Line Treatment for Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

SAN FRANCISCO and SUZHOU, China, Nov. 4, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (...

2021-11-04 17:00 3526

Innovent and NeoCura Announce Strategic Collaboration to Study the Combination Therapy of Sintilimab and Neoantigen Vaccine NEO_PLIN2101 for Cancer Treatment in China

SAN FRANCISCO and SUZHOU, China, Oct. 28, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ...

2021-10-28 08:00 2767

Innovent Announces ORIENT-31, a Phase 3 Study of Sintilimab in Patients with EGFR-Mutated Nonsquamous Non-Small Cell Lung Cancer with Prior EGFR-TKI Treatment, Has Met Primary Endpoint

SAN FRANCISCO and SUZHOU, China, Oct. 18, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2021-10-18 08:00 4022

Innovent Announces the First Patient Dosed in the Phase I/II Study of IBI351 (KRAS G12C inhibitor) in Patients with Advanced Malignant Tumors

SAN FRANCISCO and SUZHOU, China, Sept. 30, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent)...

2021-09-30 08:00 3102

Innovent Releases Preliminary Results of the Phase Ia Dose-Escalation study of IBI315 (Anti-Her2/PD-1 Bispecific Antibody) in Patients with Advanced Solid Tumors at CSCO Annual Meeting 2021

SAN FRANCISCO and SUZHOU, China, Sept. 29, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent...

2021-09-29 08:00 3115

Innovent and UNION Therapeutics Enter into Strategic Collaboration and License Agreement for Orismilast, a Next-generation PDE4 Inhibitor for Inflammatory Dermatology Conditions

SAN FRANCISCO and SUZHOU, China and HELLERUP, Denmark, Sept. 28, 2021 /PRNewswire/ -- Innovent Biol...

2021-09-28 08:00 3421